DeepMed Research

Jacobio Pharmaceuticals Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: JAB-23E73

First Posted Date: 2025-05-15

Last Posted Date: 2025-05-15

Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Target Recruit Count: 294

Registration Number: NCT06973564

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 1 locations

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: JAB-23E73

First Posted Date: 2025-05-06

Last Posted Date: 2025-05-06

Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Target Recruit Count: 334

Registration Number: NCT06959615

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
ShanXi Cancer Hospital, Taiyuan, Shanxi, China

and more 1 locations

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Phase 3

Recruiting

Conditions: Advanced Non-squamous Non-small-cell Lung Cancer
Metastatic Non-squamous Non Small Cell Lung Cancer

Interventions: Drug: JAB-21822
Drug: Tislelizumab
Drug: JAB-3312
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2024-05-16

Last Posted Date: 2025-04-04

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 392

Registration Number: NCT06416410

Locations: 🇨🇳
Anhui Province cancer hospital, Hefei, Anhui, China
🇨🇳
Pecking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing, China

and more 34 locations

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: JAB-30355

First Posted Date: 2024-04-26

Last Posted Date: 2025-04-18

Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Target Recruit Count: 144

Registration Number: NCT06386146

Locations: 🇨🇳
Research Site, Shanghai, Shanghai, China
🇺🇸
Research site, Houston, Texas, United States

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: JAB-21822
Drug: Midazolam , Rosuvastatin calcium and digoxin
Drug: Itraconazole
Drug: Rifampicin
Drug: Omeprazole

First Posted Date: 2023-12-08

Last Posted Date: 2025-04-04

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 66

Registration Number: NCT06162169

Locations: 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Phase 2

Recruiting

Conditions: KRAS P.G12C
Pancreatic Cancer
Solid Tumor

Interventions: Drug: JAB-21822

First Posted Date: 2023-08-23

Last Posted Date: 2025-04-09

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 88

Registration Number: NCT06008288

Locations: 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 28 locations

Mass Balance Study of [14C]JAB-21822

Phase 1

Completed

Conditions: Mass Balance Study in Healthy Subjects

Interventions: Drug: [14C]JAB-21822

First Posted Date: 2023-06-27

Last Posted Date: 2025-04-04

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 6

Registration Number: NCT05920941

Locations: 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Food Effect Study of JAB-21822 in Healthy Subjects

Phase 1

Completed

Conditions: Food Effect in Healthy Participants

Interventions: Drug: JAB-21822

First Posted Date: 2023-05-25

Last Posted Date: 2025-04-04

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 18

Registration Number: NCT05875493

Locations: 🇨🇳
Beijing GoBroad Boren Hospital, Beijing, Beijing, China

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: ER+ Breast Cancer
ARID1A Gene Mutation
Solid Tumors
Triple Negative Breast Cancer, TNBC
Small Cell Lung Cancer, SCLC

Interventions: Drug: JAB-2485 (Aurora A inhibitor)

First Posted Date: 2022-08-05

Last Posted Date: 2023-01-06

Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Target Recruit Count: 102

Registration Number: NCT05490472

Locations: 🇨🇳
Research site01, Changchun, Jilin, China
🇨🇳
Research site02, Beijing, Beijing, China
🇺🇸
University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States

and more 2 locations

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Phase 1

Recruiting

Conditions: Non-small Cell Lung Cancer
KRAS P.G12C
Colorectal Cancer
Pancreatic Ductal Carcinoma

Interventions: Drug: JAB-21822
Drug: JAB-3312

First Posted Date: 2022-03-21

Last Posted Date: 2025-04-04

Lead Sponsor: Allist Pharmaceuticals, Inc.

Target Recruit Count: 240

Registration Number: NCT05288205

Locations: 🇨🇳
The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Pecking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing, China

and more 24 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy